Combined use of 0.1% fluorometholone and meibomian gland expression improves symptoms of moderate and severe dry eye disease, even in patients with systemic immune disease

Figures & data

Table 1. Clinical data of dry eye patients.

Parameters		Values
No. of patients (eyes)		48 (96)
No. (percentage) of females		36 (75%)
Age (year)		60.2 ± 9.1 (range, 45–83)
No. (percentage) of patients with systemic immune disease	RA	8 (16.7%)
	Sjögren's syndrome	6 (12.5%)
	Sarcoidosis	1 (2.1%)
No. (percentage) of patients with combined eye diseases	SLK	4 (4.2%)
	Filamentosa keratitis	10 (10.4%)
	Ametropia	30 (31.3%)
History of drug use		0.1% sodium hyaluronate, polyethylene glycol eye drops, Carbomer

Figure 1. Effect of combination treatment on the tear breakup time, Schirmer I test, and fluorescein staining of non-SID patients. Thirty-three patients (66 eyes) were included. *P < 0.05 compared with Day 0; ***P < 0.001 compared with Day 0.

Figure 2. Effect of combination treatment on meibum score, meiboscore and R-scan in non-SID patients. Thirty-three patients (66 eyes) were included. *P < 0.05 compared with Day 0; ***P < 0.001 compared with Day 0.

Figure 3. Ocular surface parameters in SID patients. Fifteen patients (30 eyes) were included. *P < 0.05 compared with Day 0; **P < 0.01 compared with Day 0; ***P < 0.001 compared with Day 0.

Figure 4. Comparison of Schirmer I test results, fluorescein staining scores and tear break up time (tBUT) between SID patients and non-SID patients. *P < 0.05; **P < 0.01; ***P < 0.001.

Availability of data and materials

The datasets used and/or analyzed in the present study are available from the corresponding author upon reasonable request.